Real-time Monitoring of Kidney Grafts on Hypothermic Machine Perfusion (REMO-HYMAP)
Transplant;Failure,Kidney
About this trial
This is an interventional basic science trial for Transplant;Failure,Kidney focused on measuring creatinine, microdialysis
Eligibility Criteria
Inclusion Criteria:
- All organs to be used in the study must be intended for transplantation and not already rejected/discarded.
- All organs must be sourced from deceased donors through NHSBT in the normal course of clinical activity.
- Kidneys must come from marginal or 'imperfect' donors according to current clinical criteria. This typically indicates an age of 60 and over, or 50 and over with one or more premorbid conditions, including renal impairment, cerebrovascular disease, and hypertension.
Exclusion Criteria:
- Organs from living donors are excluded.
- Organs from young healthy donors are excluded.
- Organs will be excluded if on the assessment of the clinical team they are not suitable for hypothermic machine perfusion. This indicates organs that have arrived with visible defects, or fall well outside the team's standard criteria for clinical acceptability (excessive time in transit, excessive warm ischaemia time, excessive cold ischaemia time, very poor pre-morbid donor condition).
Sites / Locations
- Hammersmith HospitalRecruiting
Arms of the Study
Arm 1
Experimental
Marginal Kidneys
Transplant patients receiving kidneys from deceased marginal donors: aged >= 60, or >= 50 with comorbid renal impairment, hypertension, or cerebrovascular disease. Following consent, kidneys will be cold perfused with preserving solution for 2-4 hours as per standard of care at the study centre. During this period, the kidneys will be monitored for creatinine, glucose, and lactate concentrations using three microdialysis probes placed into the tissue, the vein, and the ureter. Data will be blinded to clinicians. The probes will be removed at the end of the perfusion period and the organs will be transplanted or discarded according to clinical protocol. If transplanted, the study will monitor the patient's recovery for the first 30 days.